Suggestions for re-purposing of Siddha Herbal formulations to COVID-19 positive patients with comorbidity - A review

Authors

  • Esaivani S Research officer (Siddha), Non-Communicable Disease Research Division, Department of Clinical Research, Siddha Central Research Institute, Central Council for Research in Siddha. India.
  • Kavitha Tamilarasan Research officer (Siddha), Non-Communicable Disease Research Division, Department of Clinical Research, Siddha Central Research Institute, Central Council for Research in Siddha. India.
  • Susila Rathinam Research Officer (Siddha), In-charge, Siddha Clinical Research unit, New Delhi, Central Council for Research in Siddha. India.
  • Usha Ayyasamy Research Officer (Siddha), Non-Communicable Disease Research Division, Department of Clinical Research, Siddha Central Research Institute, Central Council for Research in Siddha. India.
  • Kannan Muthiah Research Officer (Siddha), In-charge, Siddha Clinical Research unit, Bengaluru, Central Council for Research in Siddha. India.
  • Sathiyarajeswaran Parameswaran Director and In-charge, Siddha Regional Research institute Pondicherry, Central Council for Research in Siddha. India.

DOI:

https://doi.org/10.47552/ijam.v16i3.5497

Keywords:

Antiviral, Comorbidity, COVID-19, Herbal Formulations, Personalization, Traditional medicines, Siddha

Abstract

SARS-CoV-2 causes COVID-19, a disease that has killed millions of people around the world. Comorbidities are non-communicable diseases that account for roughly two- thirds of all deaths worldwide. COVID-19 mortality risk rises with age, particularly in males over 60 and in those with chronic diseases such diabetes, cancer, and cardiovascular disease. The key variables for COVID-19 vulnerability have been identified as advanced age and underlying illnesses. There is currently no new drug available to combat this fatal illness. Siddha is a traditional system of medicine which has many Herbal formulations with antiviral activity and anti-inflammatory activity. The pharmacological actions of Siddha Herbal formulations which was already in practice for the above-mentioned comorbidities were reviewed by searching key words botanical names and pharmacological actions against COVID -19 and botanical names in Google Scholar and PubMed databases. Here, we explore the scientific evidences of Siddha Herbal formulations which has antiviral, anti-inflammatory, anti-oxidant, anti-platelet, and immune-modulator actions for re-purposing them in the management of Covid-19 with comorbidity.

Downloads

Published

2025-09-30

How to Cite

S, E., Tamilarasan, K., Rathinam, S., Ayyasamy, U., Muthiah, K., & Parameswaran, S. (2025). Suggestions for re-purposing of Siddha Herbal formulations to COVID-19 positive patients with comorbidity - A review. International Journal of Ayurvedic Medicine, 16(3), 591–599. https://doi.org/10.47552/ijam.v16i3.5497

Issue

Vol. 16 No. 3 (2025): July - September 2025

Section

Review Articles

License

Copyright (c) 2025 International Journal of Ayurvedic Medicine

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

The author hereby transfers, assigns, or conveys all copyright ownership to the International Journal of Ayurvedic Medicine (IJAM). By this transfer, the article becomes the property of the IJAM and may not be published elsewhere without written permission from the IJAM.

This transfer of copyright also implies transfer of rights for printed, electronic, microfilm, and facsimile publication. No royalty or other monetary compensation will be received for transferring the copyright of the article to the IJAM.

The IJAM, in turn, grants each author the right to republish the article in any book for which he or she is the author or editor, without paying royalties to the IJAM, subject to the express conditions that (a) the author notify IJAM in advance in writing of this republication and (b) a credit line attributes the original publication to IJAM.

https://creativecommons.org/licenses/by-nc-sa/4.0/